6533b81ffe1ef96bd1277c01

RESEARCH PRODUCT

Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases – A systematic review

Jochen JackowskiAndrea Maria Schmidt-westhausenFrank Peter StrietzelPeter A. ReichartKonrad Neumann

subject

medicine.medical_specialtyDatabases FactualReviewScleroderma03 medical and health sciences0302 clinical medicinemedicineHumansLupus Erythematosus SystemicDental Restoration Failureskin and connective tissue diseasesGeneral DentistrySurvival rateDental ImplantsScleroderma SystemicLupus erythematosusintegumentary systembusiness.industryDental prosthesis030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in Dentistrymedicine.diseaseDermatologystomatognathic diseasesPemphigusSjogren's SyndromeTreatment OutcomeOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusDental Prosthesis Implant-SupportedImplantEpidermolysis bullosaEpidermolysis BullosaMouth DiseasesbusinessPemphigusLichen Planus Oral

description

Background To give an overview on implant survival rates in patients with oral manifestations of systemic autoimmune (oral Lichen planus (oLp), Pemphigus (Pe)), muco-cutaneous (Epidermolysis bullosa (EB)), autoimmune multisystemic rheumatic diseases (Sjögren´s syndrome (SjS), systemic Lupus erythematosus (sLE), or systemic Sclerosis (sSc)). Material and Methods Systematic literature review (PubMed/Medline, Embase) using MESH and search term combinations, published between 1980 and August 2018 in English language reporting on dental implant-prosthetic rehabilitation of patients with oLp, Pe, EB, SjS, sLE, sSc, study design, age, gender, follow-up period (≥ 12 months), implant survival rate. Implant-related weighed mean values of implant survival rate (wmSR) were calculated. Results After a mean follow-up period (mfp) of 44.6 months, a wmSR of 98.3 % was calculated from data published for patients with oLp (100 patients with 302 implants). Data of 27 patients (152 implants) with EB revealed wmSR of 98.7 % following mfp of 32.6 months. For 71 patients (272 implants) with SjS, wmSR was 94.2 % following a mfp of 45.2 months, and for 6 patients (44 implants) with sSc, wmSR was 97.7 % after mfp of 37.5 months. One case report on one patient each with Pe (two implants) as well as sLE (6 implants) showed 100 % SR following at least 24 months. Conclusions Guidelines regarding implant treatment of patients with oLp, Pe, EB, SjS, sLE or sSc do not exist nor are contraindicating conditions defined. Implant survival rates of patients affected are comparable to those of healthy patients. For implant-prosthetic rehabilitation of patients with Pe and sLE no conclusions can be drawn due to lack of sufficient clinical data. Implant-prosthetic treatment guidelines regarding healthy patients should be strictly followed, but frequent recall is recommended in patients affected with oLp, SjS, EB, SSc, Pe or sLE. Key words:Dental implants, implant supported prosthesis, oral lichen planus, Sjögren´s syndrome, epidermolysis bullosa, systemic sclerosis, pemphigus, systemic lupus erythematosus.

yearjournalcountryeditionlanguage
2018-09-24Medicina Oral Patología Oral y Cirugia Bucal
https://doi.org/10.4317/medoral.22786